Trial Profile
Long-acting release formulation of pasireotide in patients with Cushing's disease: A randomised phase III study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- 03 Jun 2016 New trial record
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society